Table 2.
Univariate and multivariate analysis for progression‐free survival
| Category | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p valuea | HR (95% CI) | p valuea | |
| KRAS exon 2 mutation: G12C vs. non‐G12C | 1.47 (1.08–2.01) | .015 | 1.43 (1.04–1.96) | .030 |
| Age: ≥65 vs. <65 years | 0.97 (0.83–1.14) | .724 | ||
| Gender: Male vs. female | 0.98 (0.83–1.15) | .794 | ||
| ECOG PS: 1 or 2 vs. 0 | 1.48 (1.24–1.78) | <.001 | 1.08 (0.88–1.33) | .443 |
| Primary tumor site: left vs. right | 0.93 (0.79–1.10) | .417 | ||
| Surgery on primary tumor: Yes vs. No | 0.69 (0.59–0.81) | <.001 | 0.82 (0.69–0.99) | .035 |
| Time of first metastasis: Synchronous vs. metachronous | 1.15 (0.97–1.35) | .113 | ||
| Histology: Poor/muc vs. well/mod | 1.17 (0.89–1.54) | .258 | ||
| Serum LDH, IU/L: ≥210 (median) vs. <210 | 1.50 (1.28–1.76) | <.001 | 1.24 (1.04–1.47) | .014 |
| GPS: 1 or 2 vs. 0 | 1.96 (1.58–2.44) | <.001 | 1.53 (1.21–1.93) | <.001 |
| Number of metastatic organ sites: ≥2 vs. 1 | 1.46 (1.25–1.71) | <.001 | 1.32 (1.12–1.55) | .001 |
| First‐line backbone regimen: Doubletb or tripletc vs. monod | 0.84 (0.57–1.22) | .355 | ||
| First‐line bevacizumab: Yes vs. no | 0.51 (0.42–0.63) | <.001 | 0.57 (0.45–0.71) | <.001 |
a
Values of p were calculated using the Cox proportional hazard model.
b
Doublet indicates oxaliplatin‐based regimens (FOLFOX, CAPOX, and SOX) or irinotecan‐based regimens (FOLFIRI, IRIS [SIRB], CAPIRI).
c
Triplet indicates FOLFOXIRI.
d
Mono indicates 5‐fluorouracil (5‐FU)/leucovorin (LV), capecitabine, tegafur‐uracil (UFT)/LV, or S‐1 monotherapy.
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; GPS, Glasgow prognostic score; HR, hazard ratio; KRAS, Kirsten rat sarcoma; LDH, lactate dehydrogenase; mod, moderately differentiated; muc, mucinous adenocarcinoma; poor, poorly differentiated; well, well differentiated.